<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1561">
  <stage>Registered</stage>
  <submitdate>14/05/2007</submitdate>
  <approvaldate>14/05/2007</approvaldate>
  <nctid>NCT00474188</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma</studytitle>
    <scientifictitle>A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid ®) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CC-5013-NHL-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diffuse Large B-cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CC-5013 (lenalidomide)
Treatment: drugs - dexamethasone

Experimental: Single Arm - 


Treatment: drugs: CC-5013 (lenalidomide)
Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle

Treatment: drugs: dexamethasone
Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumor Response Rate</outcome>
      <timepoint>One Year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor Control Rate</outcome>
      <timepoint>One Year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Progression</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free Survival</outcome>
      <timepoint>One year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Biopsy-proven diffuse large B-cell non-Hodgkin's lymphoma

          -  Relapsed or refractory to previous therapy for non-Hodgkin's lymphoma

          -  Measurable disease on cross sectional imaging that is at least 2 cm in the longest
             diameter

          -  ECOG performance score of 0,1 or 2

          -  Willing to follow the pregnancy precautions</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any of the following laboratory abnormalities.

          -  Absolute neutrophil count (ANC) &lt; 1,500 cells/mm3 (1.5 x 109/L).

          -  Platelet count &lt; 60,000/mm3 (60 x 109/L).

          -  Serum SGOT/AST or SGPT/ALT 5.0 x upper limit of normal (ULN).

          -  Serum total bilirubin &gt; 2.0 mg/dL (34 µmol/L).

          -  Subjects who are candidates for and willing to undergo an autologous stem cell
             transplant.

          -  History of active CNS lymphoma within the previous 3 months

          -  Subjects not willing or unable to take DVT prophylaxis

          -  History of other malignancies within the past year

          -  Positive HIV or active Hepatitis B or C</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>26</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>HOCA - South Brisbane</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <postcode>VIC3050 - Melbourne</postcode>
    <postcode>VIC 3199 - Frankston</postcode>
    <postcode>QLD 4101 - South Brisbane</postcode>
    <postcode>VIC 3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Celgene Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with
      dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00474188</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>